Core Laboratories N.V. (CLB)
NYSE:CLB
Want to see CLB full AI Analyst Report?
CLB Stock Chart & Stats
$16.27
-$0.34(-1.84%)
At close: 4:00 PM EST
$16.27
-$0.34(-1.84%)
Day’s Range― - ―
52-Week Range$9.72 - $20.36
Previous CloseN/A
Volume23.26K
Average Volume (3M)411.26K
Market Cap
$647.90M
Enterprise Value$666.37M
Total Cash (Recent Filing)$22.82M
Total Debt (Recent Filing)$41.28M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Jul 29, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend Yield0.24%
Share Statistics
EPS (TTM)0.06
Shares Outstanding46,048,267
10 Day Avg. Volume423,711
30 Day Avg. Volume411,263
Financial Highlights & Ratios
PEG Ratio15.70
Price to Book (P/B)2.66
Price to Sales (P/S)1.42
P/FCF Ratio33.00
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue1.27
Enterprise Value/Gross Profit7.12
Enterprise Value/Ebitda9.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.64
Revenue Forecast (FY)$508.42M
Bulls Say, Bears Say
Bulls Say
Geopolitical TensionsPotential easing of geopolitical tensions between Russia and Ukraine could serve as a positive catalyst for the company.
Research And DevelopmentThe Research and Development division is expected to grow, likely outpacing international upstream capital expenditure growth.
Bears Say
Production Enhancement ChallengesProduction Enhancement has shrunk to just 11% of total company operating income, indicating challenges in that segment.
Core Laboratories News
CLB FAQ
What was Core Laboratories N.V.’s price range in the past 12 months?
Core Laboratories N.V. lowest stock price was $9.72 and its highest was $20.36 in the past 12 months.
What is Core Laboratories N.V.’s market cap?
Core Laboratories N.V.’s market cap is $647.90M.
When is Core Laboratories N.V.’s upcoming earnings report date?
Core Laboratories N.V.’s upcoming earnings report date is Jul 29, 2026 which is in 86 days.
How were Core Laboratories N.V.’s earnings last quarter?
Core Laboratories N.V. released its earnings results on Apr 29, 2026. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.095 by -$0.035.
Is Core Laboratories N.V. overvalued?
According to Wall Street analysts Core Laboratories N.V.’s price is currently Overvalued.
Does Core Laboratories N.V. pay dividends?
Core Laboratories N.V. pays a Quarterly dividend of $0.01 which represents an annual dividend yield of 0.24%. See more information on Core Laboratories N.V. dividends here
What is Core Laboratories N.V.’s EPS estimate?
Core Laboratories N.V.’s EPS estimate is 0.11.
How many shares outstanding does Core Laboratories N.V. have?
Core Laboratories N.V. has 46,048,267 shares outstanding.
What happened to Core Laboratories N.V.’s price movement after its last earnings report?
Core Laboratories N.V. reported an EPS of $0.06 in its last earnings report, missing expectations of $0.095. Following the earnings report the stock price went down -15.318%.
Which hedge fund is a major shareholder of Core Laboratories N.V.?
Currently, no hedge funds are holding shares in CLB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Core Laboratories Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
CLB Sentiment 50%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 424.0K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.24%
12-Months-Change
Fundamentals
Return on Equity
11.94%
Trailing 12-Months
Asset Growth
-0.64%
Trailing 12-Months
Company Description
Core Laboratories N.V.
Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, reservoir fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, and production. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. In addition, the company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. It operates approximately in 50 countries. The company was founded in 1936 and is based in Amstelveen, the Netherlands.
CLB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call mixed clear operational and technological strengths (notable product wins, digital data progress, continued shareholder returns and a constructive multi‑year market outlook) with acute near-term headwinds. Q1 showed meaningful sequential revenue declines, sharp margin compression and steep earnings deterioration driven by the Middle East conflict, Russia/Ukraine disruptions, severe weather and higher costs—offset only partially by product/diagnostic demand in select regions and ongoing capital returns. Management expects modest sequential improvement in Q2 but the near-term outlook is still clouded by geopolitical and operational uncertainty.View all CLB earnings summariesTechnical Analysis
Flotek
―
Oil States International
―
Tetra Technologies
―
Propetro Holding
―
ProFrac Holding
―
Ownership Overview
1.07% Insiders
34.86% Mutual Funds
4.92% Other Institutional Investors
34.76% Public Companies and
Individual Investors